GSK terminates RA project

Yesterday, the British pharma giant GSK announced that they are terminating the development of the candidate otilimab for rheumatoid arthritis after it failed to reach the primary endpoint in a phase III study in patients with an inadequate response to biological DMARDs and/or JAK inhibitors.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/10/gsk-terminates-ra-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/